NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer.

NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer.
复制标题

NDRG1 通过调节结直肠癌中 EGFR 的运输来增强西妥昔单抗的敏感性

DOI:
10.1038/s41388-021-01962-8
复制
发表时间:
2021-10
期刊:
影响因子:
8
通讯作者:
Ma J
Ma J
中科院分区:
医学1区
文献类型:
--
作者:
Yang G;Huang L;Jia H;Aikemu B;Zhang S;Shao Y;Hong H;Yesseyeva G;Wang C;Li S;Sun J;Zheng M;Ma J

文献摘要

参考文献

被引文献

相似文献

N-myc下游调节基因1(NDRG 1)是与许多经典肿瘤信号通路相互作用的关键调节因子,包括表皮生长因子受体(EGFR)下游的一些分子。然而,NDRG 1是否参与了西妥昔单抗(CTX)耐药的机制,第一个针对EGFR的单克隆抗体尚未报道。在这里,我们发现NDRG 1增强了结肠直肠癌(CRC)细胞系对CTX的敏感性。随后,我们确定了这种现象的潜在机制。NDRG 1抑制EGFR的表达,阻断EGFR的磷酸化,减少EGFR在细胞膜、细胞质和细胞核中的分布。NDRG 1抑制EGFR下游信号通路RAS/RAF/ERK和PI 3 k/AKT/mTOR。此外,我们发现NDRG 1减弱caveolin-1(Cav 1)诱导的EGFR的内吞和降解。此外,我们的研究结果在动物模型和人体组织中进一步观察。我们的研究结果代表了一个潜在的重大发现,解释了NDRG 1在CTX耐药中的机制。NDRG 1可能是一个有前途的生物标志物,以预测最佳的反应,CTX,并在转移性CRC(mCRC)的治疗中的关键目标,以提高CTX的活性。
N-myc downstream-regulated gene 1 (NDRG1) is a key regulator that interacts with many classic tumor signaling pathways, including some molecules downstream of the epidermal growth factor receptor (EGFR). However, whether NDRG1 is involved in the mechanism of resistance to cetuximab (CTX), the first monoclonal antibody targeting the EGFR has not been reported. Here, we found that NDRG1 enhanced the sensitivity of CTX in colorectal cancer (CRC) cell lines. Afterwards, we determined the underlying mechanism of this phenomenon. We demonstrated that NDRG1 inhibited the expression of EGFR; blocked EGFR phosphorylation and reduced the EGFR distribution in the cell membrane, cytoplasm and nucleus. And then, NDRG1 suppressed the EGFR downstream signaling: RAS/RAF/ERK and PI3k/AKT/mTOR pathways. Moreover, we discovered that NDRG1 attenuated the endocytosis and degradation of EGFR induced by caveolin-1 (Cav1). Additionally, our findings were further observed in an animal model and human tissues. Our results represent a potentially significant discovery that explains the mechanisms of NDRG1 in CTX resistance. NDRG1 could be a promising biomarker to predict optimum responses to CTX, and a key target to enhance CTX activity in the treatment of metastatic CRC (mCRC).
DOI: 10.1016/j.ejca.2008.10.026
发表时间: 2009-01-01
影响因子: 8.4
作者:
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者: Verweij, J.
研究EGF受体的内吞运输的方法。
DOI: 10.1016/bs.mcb.2015.05.008
发表时间: 2015
影响因子: --
作者:
Pinilla-Macua I;Sorkin A
通讯作者: Sorkin A
DOI: 10.1007/978-3-319-96704-2_9
发表时间: 2018-01-01
期刊: ENDOCYTOSIS AND SIGNALING
影响因子: --
作者:
Caldieri, Giusi;Malabarba, Maria Grazia;Sigismund, Sara
通讯作者: Sigismund, Sara
DOI: 10.3322/caac.21395
发表时间: 2017-05-01
影响因子: 254.7
作者:
Siegel, Rebecca L.;Miller, Kimberly D.;Jemal, Ahmedin
通讯作者: Jemal, Ahmedin
DOI: 10.1074/jbc.272.10.6525
发表时间: 1997-03-07
影响因子: 4.8
作者:
Couet, J;Li, SW;Lisanti, MP
通讯作者: Lisanti, MP